Combinatorial Cancer Immunotherapies

Advances in Immunology

Volumn 130, Issue , 2016, Pages 251-277

  Hellmann, Matthew D ^a,b   Friedman, Claire F ^a,b   Wolchok, Jedd D ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

4 1BB CD137; Chemotherapy; Combination immunotherapy; CTLA 4; GITR; IDO; IL 2; LAG 3; Oncolytic virus; OX 40; PD 1; PD L1; Radiation; T cell checkpoint blockade; TIM 3

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; ATEZOLIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DURVALUMAB; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; ONCOLYTIC NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIRUS; PACLITAXEL; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; SUNITINIB; TALIMOGENE LAHERPAREPVEC; TICILIMUMAB; UNCLASSIFIED DRUG; URELUMAB; ANTINEOPLASTIC AGENT; T LYMPHOCYTE RECEPTOR;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; ENDOCRINE DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOPATHOLOGY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER TOXICITY; LOW DRUG DOSE; MELANOMA; MELANOMA B16; METASTATIC MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; OPTIMAL DRUG DOSE; OVARY CANCER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RASH; SMALL CELL LUNG CANCER; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; MOUSE; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; COMBINED MODALITY THERAPY; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; HUMANS; IMMUNOTHERAPY; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOLYTIC VIRUSES; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84954285734     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/bs.ai.2015.12.005     Document Type: Chapter

References (170)

1. Agata Y., Kawasaki A., Nishimura H., et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. International Immunology 1996, 8(5):765-772.
2. al-Shamkhani A., Birkeland M.L., Puklavec M., Brown M.H., James W., Barclay A.N. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. European Journal of Immunology 1996, 26(8):1695-1699.
3. Andtbacka R.H., Kaufman H.L., Collichio F., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of Clinical Oncology 2015, 33:2780-2788.
4. Ansell S.M., Lesokhin A.M., Borrello I., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England Journal of Medicine 2015, 372(4):311-319.
5. Antonia S.J., Bendell J.C., Taylor M.H., et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. American Society of Clinical Oncology Meeting Abstracts 2015, 33(15 suppl):7503.
6. Antonia S.J., Brahmer J.R., Gettinger S.N., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). American Society of Clinical Oncology Meeting Abstracts 2014, 32(15 suppl):8113.
7. Antonia S.J., Gettinger S.N., Chow L.Q.M., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. American Society of Clinical Oncology Meeting Abstracts 2014, 32(15 suppl):8023.
8. Antonia S.J., Goldberg S.B., Balmanoukian A.S., et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. American Society of Clinical Oncology Meeting Abstracts 2015, 33(15 suppl):3014.
9. Arestides R.S., He H., Westlake R.M., et al. Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. European Journal of Immunology 2002, 32(10):2874-2880.
10. Atkins M.B., Lotze M.T., Dutcher J.P., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1999, 17(7):2105-2116.
11. Baixeras E., Huard B., Miossec C., et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. The Journal of Experimental Medicine 1992, 176(2):327-337.
12. Bansal-Pakala P., Halteman B.S., Cheng M.H., Croft M. Costimulation of CD8 T cell responses by OX40. Journal of Immunology 2004, 172(8):4821-4825.
13. Barber D.L., Wherry E.J., Masopust D., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439(7077):682-687.
14. Baum P.R., Gayle R.B., Ramsdell F., et al. Molecular characterization of murine and human OX40/OX40 ligand systems: Identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. The EMBO Journal 1994, 13(17):3992-4001.
15. Bennett F., Luxenberg D., Ling V., et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. Journal of Immunology 2003, 170(2):711-718.
16. Bowen R.C., Meek S., Williams M., et al. A phase I study of intratumoral injection of ipilimumab and interleukin-2 in patients with unresectable stage III-IV melanoma. American Society of Clinical Oncology Meeting Abstracts 2015, 33(15 suppl):3018.
17. Brahmer J.R., Drake C.G., Wollner I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology 2010, 28(19):3167-3175.
18. Brahmer J., Reckamp K.L., Baas P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. The New England Journal of Medicine 2015, 373:123-135.
19. Brunner M.C., Chambers C.A., Chan F.K., Hanke J., Winoto A., Allison J.P. CTLA-4-mediated inhibition of early events of T cell proliferation. Journal of Immunology 1999, 162(10):5813-5820.
20. Burnet M. Cancer: A biological approach. I. The processes of control. British Medical Journal 1957, 1(5022):779-786.
21. Burnet M. Cancer: A biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. British Medical Journal 1957, 1(5023):841-847.
22. Carreno B.M., Bennett F., Chau T.A., et al. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. Journal of Immunology 2000, 165(3):1352-1356.
23. Chemnitz J.M., Parry R.V., Nichols K.E., June C.H., Riley J.L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. Journal of Immunology 2004, 173(2):945-954.
24. Cohen A.D., Schaer D.A., Liu C., et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010, 5(5). e10436.
25. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Clinical Orthopaedics and Related Research 1893, 1991(262):3-11.
26. Curran M.A., Kim M., Montalvo W., Al-Shamkhani A., Allison J.P. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011, 6(4). e19499.
27. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(9):4275-4280.
28. Curti A., Pandolfi S., Valzasina B., et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007, 109(7):2871-2877.
29. Day C.L., Kaufmann D.E., Kiepiela P., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443(7109):350-354.
30. Deng L., Liang H., Burnette B., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. The Journal of Clinical Investigation 2014, 124(2):687-695.
31. Denkert C., von Minckwitz G., Brase J.C., et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2015, 33(9):983-991.
32. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Medicine 1999, 5(12):1365-1369.
33. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007, 370(9605):2103-2111.
34. Fallarino F., Grohmann U., You S., et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. Journal of Immunology 2006, 176(11):6752-6761.
35. Fourcade J., Sun Z., Benallaoua M., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. The Journal of Experimental Medicine 2010, 207(10):2175-2186.
36. Freeman G.J., Borriello F., Hodes R.J., et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 1993, 262(5135):907-909.
37. Freeman G.J., Long A.J., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. The Journal of Experimental Medicine 2000, 192(7):1027-1034.
38. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1995, 13(3):688-696.
39. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
40. Garnett C.T., Palena C., Chakraborty M., Tsang K.Y., Schlom J., Hodge J.W. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Research 2004, 64(21):7985-7994.
41. Garon E.B., Rizvi N.A., Hui R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine 2015, 372(21):2018-2028.
42. Ghiringhelli F., Menard C., Puig P.E., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunology, Immunotherapy: CII 2007, 56(5):641-648.
43. Gibney G.T., Hamid O., Gangadhar T.C., et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. American Society of Clinical Oncology Meeting Abstracts 2014, 32(15 suppl):3010.
44. Golden E.B., Demaria S., Schiff P.B., Chachoua A., Formenti S.C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunology Research 2013, 1(6):365-372.
45. Greene J.L., Leytze G.M., Emswiler J., et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. The Journal of Biological Chemistry 1996, 271(43):26762-26771.
46. Grimaldi A.M., Simeone E., Giannarelli D., et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014, 3. e28780.
47. Grosso J.F., Goldberg M.V., Getnet D., et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. Journal of Immunology 2009, 182(11):6659-6669.
48. Grosso J.F., Kelleher C.C., Harris T.J., et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. The Journal of Clinical Investigation 2007, 117(11):3383-3392.
49. Guo Z., Wang X., Cheng D., Xia Z., Luan M., Zhang S. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One 2014, 9(2). e89350.
50. Gupta A., Probst H.C., Vuong V., et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. Journal of Immunology 2012, 189(2):558-566.
51. Hamid O., Robert C., Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England Journal of Medicine 2013, 369(2):134-144.
52. Hammers H.J., Plimack E.R., Infante J.R., et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). American Society of Clinical Oncology Meeting Abstracts 2014, 32(15 suppl):4504.
53. Herbst R.S., Soria J.C., Kowanetz M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515(7528):563-567.
54. Hernandez-Chacon J.A., Li Y., Wu R.C., et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. Journal of Immunotherapy 2011, 34(3):236-250.
55. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010, 363(8):711-723.
56. Holmgaard R.B., Zamarin D., Munn D.H., Wolchok J.D., Allison J.P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. The Journal of Experimental Medicine 2013, 210(7):1389-1402.
57. Huang C.T., Workman C.J., Flies D., et al. Role of LAG-3 in regulatory T cells. Immunity 2004, 21(4):503-513.
58. Huard B., Tournier M., Hercend T., Triebel F., Faure F. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. European Journal of Immunology 1994, 24(12):3216-3221.
59. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO Journal 1992, 11(11):3887-3895.
60. Jin H.T., Anderson A.C., Tan W.G., et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(33):14733-14738.
61. Kanamaru F., Youngnak P., Hashiguchi M., et al. Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. Journal of Immunology 2004, 172(12):7306-7314.
62. Ko K., Yamazaki S., Nakamura K., et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. The Journal of Experimental Medicine 2005, 202(7):885-891.
63. Kohlhapp F., Broucek J., Hughes T., et al. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. Journal for Immunotherapy of Cancer 2015, 3(1):18.
64. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The Journal of Experimental Medicine 1995, 182(2):459-465.
65. Krummel M.F., Allison J.P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. The Journal of Experimental Medicine 1996, 183(6):2533-2540.
66. Larkin J., Chiarion-Sileni V., Gonzalez R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. The New England Journal of Medicine 2015, 373(1):23-34.
67. Latchman Y., Wood C.R., Chernova T., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology 2001, 2(3):261-268.
68. Le D.T., Jaffee E.M. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective. Cancer Research 2012, 72(14):3439-3444.
69. Le D.T., Wang-Gillam A., Picozzi V., et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Journal of Clinical Oncology 2015, 33(12):1325-1333.
70. Lee Y., Auh S.L., Wang Y., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment. Blood 2009, 114(3):589-595.
71. Lee H.W., Park S.J., Choi B.K., Kim H.H., Nam K.O., Kwon B.S. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. Journal of Immunology 2002, 169(9):4882-4888.
72. Linsley P.S., Bradshaw J., Greene J., Peach R., Bennett K.L., Mittler R.S. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996, 4(6):535-543.
73. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. The Journal of Experimental Medicine 1991, 174(3):561-569.
74. Linsley P.S., Greene J.L., Brady W., Bajorath J., Ledbetter J.A., Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994, 1(9):793-801.
75. Liu S.V., Powderly J.D., Camidge D.R., et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). American Society of Clinical Oncology Meeting Abstracts 2015, 33(15 suppl):8030.
76. Liu H., Zhang T., Ye J., et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunology, Immunotherapy: CII 2012, 61(10):1849-1856.
77. Lu L., Xu X., Zhang B., Zhang R., Ji H., Wang X. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. Journal of Translational Medicine 2014, 12:36.
78. Lugade A.A., Moran J.P., Gerber S.A., Rose R.C., Frelinger J.G., Lord E.M. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. Journal of Immunology 2005, 174(12):7516-7523.
79. Lynch T.J., Bondarenko I., Luft A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. Journal of Clinical Oncology 2012, 30(17):2046-2054.
80. Maker A.V., Phan G.Q., Attia P., et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Annals of Surgical Oncology 2005, 12(12):1005-1016.
81. Mallett S., Fossum S., Barclay A.N. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes-A molecule related to nerve growth factor receptor. The EMBO Journal 1990, 9(4):1063-1068.
82. Mao Y., Qu Q., Zhang Y., Liu J., Chen X., Shen K. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis. PLoS One 2014, 9(12). e115103.
83. Marabelle A., Kohrt H., Sagiv-Barfi I., et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. The Journal of Clinical Investigation 2013, 123(6):2447-2463.
84. McMahan R.H., Golden-Mason L., Nishimura M.I., et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. The Journal of Clinical Investigation 2010, 120(12):4546-4557.
85. Melero I., Shuford W.W., Newby S.A., et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Medicine 1997, 3(6):682-685.
86. Mitsui J., Nishikawa H., Muraoka D., et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16(10):2781-2791.
87. Miyazaki T., Dierich A., Benoist C., Mathis D. LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice. International Immunology 1996, 8(5):725-729.
88. Mole R.H. Whole body irradiation: Radiobiology or medicine?. The British Journal of Radiology 1953, 26(305):234-241.
89. Monney L., Sabatos C.A., Gaglia J.L., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415(6871):536-541.
90. Montagnoli C., Fallarino F., Gaziano R., et al. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. Journal of Immunology 2006, 176(3):1712-1723.
91. Morales A., Eidinger D., Bruce A.W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. The Journal of Urology 1976, 116(2):180-183.
92. Motzer R.J., Rini B.I., McDermott D.F., et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. Journal of Clinical Oncology 2015, 33(13):1430-1437.
93. Munn D.H., Sharma M.D., Baban B., et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005, 22(5):633-642.
94. Munn D.H., Zhou M., Attwood J.T., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281(5380):1191-1193.
95. Ngiow S.F., von Scheidt B., Akiba H., Yagita H., Teng M.W., Smyth M.J. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Research 2011, 71(10):3540-3551.
96. Nishikawa H., Kato T., Hirayama M., et al. Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Research 2008, 68(14):5948-5954.
97. Nishimura H., Nose M., Hiai H., Minato N., Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11(2):141-151.
98. Nishimura H., Okazaki T., Tanaka Y., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291(5502):319-322.
99. Okazaki T., Okazaki I.M., Wang J., et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. The Journal of Experimental Medicine 2011, 208(2):395-407.
100. Okazaki T., Tanaka Y., Nishio R., et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nature Medicine 2003, 9(12):1477-1483.
101. Papadimitrakopoulou V., Patnaik A., Borghaei H., et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. American Society of Clinical Oncology Meeting Abstracts 2015, 33(15 suppl):8031.
102. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer 2012, 12(4):252-264.
103. Parker J.J., Jones J.C., Strober S., Knox S.J. Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. Clinical Immunology 2013, 148(1):44-55.
104. Parry R.V., Chemnitz J.M., Frauwirth K.A., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Molecular and Cellular Biology 2005, 25(21):9543-9553.
105. Piconese S., Pittoni P., Burocchi A., et al. A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2. European Journal of Immunology 2010, 40(10):2902-2913.
106. Postow M.A., Callahan M.K., Barker C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. The New England Journal of Medicine 2012, 366(10):925-931.
107. Postow M.A., Chesney J., Pavlick A.C., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. The New England Journal of Medicine 2015, 372:2006-2017.
108. Powles T., Eder J.P., Fine G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515(7528):558-562.
109. Puzanov I., Milhem M.M., Andtbacka R.H.I., et al. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. American Society of Clinical Oncology Meeting Abstracts 2015, 33(15 suppl):9063.
110. Reck M., Bondarenko I., Luft A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2013, 24(1):75-83.
111. Redmond W.L., Linch S.N., Kasiewicz M.J. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunology Research 2014, 2(2):142-153.
112. Reits E.A., Hodge J.W., Herberts C.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. The Journal of Experimental Medicine 2006, 203(5):1259-1271.
113. Ribas A. Tumor immunotherapy directed at PD-1. The New England Journal of Medicine 2012, 366(26):2517-2519.
114. Ribas A., Puzanov I., Gajewski T., et al. A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma. American Society of Clinical Oncology Meeting Abstracts 2015, 33(15 suppl). TPS9081.
115. Rizvi N.A., Gettinger S.N., Goldman J.W., et al. Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2015, (Abstract #786).
116. Rizvi N.A., Mazieres J., Planchard D., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. The Lancet Oncology 2015, 16(3):257-265.
117. Robert C., Ribas A., Wolchok J.D., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384(9948):1109-1117.
118. Robert C., Schachter J., Long G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. The New England Journal of Medicine 2015, 372(26):2521-2532.
119. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine 2011, 364(26):2517-2526.
120. Ronchetti S., Nocentini G., Bianchini R., Krausz L.T., Migliorati G., Riccardi C. Glucocorticoid-induced TNFR-related protein lowers the threshold of CD28 costimulation in CD8+ T cells. Journal of Immunology 2007, 179(9):5916-5926.
121. Rosenberg S.A., Yang J.C., Sherry R.M., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011, 17(13):4550-4557.
122. Rosenberg S.A., Yang J.C., Topalian S.L., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA : The Journal of the American Medical Association 1994, 271(12):907-913.
123. Ruby C.E., Yates M.A., Hirschhorn-Cymerman D., et al. Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. Journal of Immunology 2009, 183(8):4853-4857.
124. Sagiv-Barfi I., Rajapaksa A., Czerwinski D., et al. Abstract 2941: Local tumor irradiation combined with α-PDL-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series. Cancer Research 2014, 74(19 Supplement):2941.
125. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. The Journal of Experimental Medicine 2010, 207(10):2187-2194.
126. Saunders P.A., Hendrycks V.R., Lidinsky W.A., Woods M.L. PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion. European Journal of Immunology 2005, 35(12):3561-3569.
127. Schaer D.A., Cohen A.D., Wolchok J.D. Anti-GITR antibodies-Potential clinical applications for tumor immunotherapy. Current Opinion in Investigational Drugs 2010, 11(12):1378-1386.
128. Schneider H., Downey J., Smith A., et al. Reversal of the TCR stop signal by CTLA-4. Science 2006, 313(5795):1972-1975.
129. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011, 331(6024):1565-1570.
130. Sevko A., Michels T., Vrohlings M., et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. Journal of Immunology 2013, 190(5):2464-2471.
131. Sharabi A.B., Nirschl C.J., Kochel C.M., et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunology Research 2015, 3(4):345-355.
132. Sharma A., Bode B., Wenger R.H., et al. γ-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One 2011, 6(11). e28217.
133. Sharma M.D., Hou D.Y., Baban B., et al. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 2010, 33(6):942-954.
134. Shevchenko I., Karakhanova S., Soltek S., et al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. International Journal of Cancer 2013, 133(1):98-107.
135. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nature Immunology 2002, 3(2):135-142.
136. Shinto E., Hase K., Hashiguchi Y., et al. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. Annals of Surgical Oncology 2014, 21(Suppl 3):S414-S421.
137. Shrikant P., Khoruts A., Mescher M.F. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 1999, 11(4):483-493.
138. Sierro S., Romero P., Speiser D.E. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opinion on Therapeutic Targets 2011, 15(1):91-101.
139. Starck L., Scholz C., Dorken B., Daniel P.T. Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. European Journal of Immunology 2005, 35(4):1257-1266.
140. Strebhardt K., Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Reviews. Cancer 2008, 8(6):473-480.
141. Sznol M., Hodi F.S., Margolin K., et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). American Society of Clinical Oncology Meeting Abstracts 2008, 26(15 suppl):3007.
142. Sznol M., Kluger H.M., Callahan M.K., et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). American Society of Clinical Oncology Meeting Abstracts 2014, 32(15 suppl). LBA9003.
143. Takeda I., Ine S., Killeen N., et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. Journal of Immunology 2004, 172(6):3580-3589.
144. Taube J.M., Klein A., Brahmer J.R., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2014, 20(19):5064-5074.
145. Thomas L. Delayed hypersensitivity in health and disease. Cellular and humoral aspects of the hypersensitive states 1959, 529-532. Hoeber-Harper, New York, NY. H.S. Lawrence (Ed.).
146. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3(5):541-547.
147. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 2012, 366(26):2443-2454.
148. Triebel F., Jitsukawa S., Baixeras E., et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. The Journal of Experimental Medicine 1990, 171(5):1393-1405.
149. Tumeh P.C., Harview C.L., Yearley J.H., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515(7528):568-571.
150. Turk M.J., Guevara-Patino J.A., Rizzuto G.A., Engelhorn M.E., Sakaguchi S., Houghton A.N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. The Journal of Experimental Medicine 2004, 200(6):771-782.
151. Twyman-Saint Victor C., Rech A.J., Maity A., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520(7547):373-377.
152. Umansky V., Sevko A. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunology, Immunotherapy: CII 2012, 61(2):275-282.
153. Vacchelli E., Aranda F., Eggermont A., et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014, 3(10). e957994.
154. Valzasina B., Guiducci C., Dislich H., Killeen N., Weinberg A.D., Colombo M.P. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: A novel regulatory role for OX40 and its comparison with GITR. Blood 2005, 105(7):2845-2851.
155. Vinay D.S., Kwon B.S. 4-1BB signaling beyond T cells. Cellular & Molecular Immunology 2011, 8(4):281-284.
156. Vinay D.S., Kwon B.S. Immunotherapy of cancer with 4-1BB. Molecular Cancer Therapeutics 2012, 11(5):1062-1070.
157. Vincent J., Mignot G., Chalmin F., et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Research 2010, 70(8):3052-3061.
158. Walunas T.L., Bakker C.Y., Bluestone J.A. CTLA-4 ligation blocks CD28-dependent T cell activation. The Journal of Experimental Medicine 1996, 183(6):2541-2550.
159. Walunas T.L., Lenschow D.J., Bakker C.Y., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1(5):405-413.
160. Waterhouse P., Penninger J.M., Timms E., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270(5238):985-988.
161. Weber J.S., D'Angelo S.P., Minor D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. The Lancet Oncology 2015, 16(4):375-384.
162. Weber J., Hamid O., Amin A., et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immunity 2013, 13:7.
163. Weinberg A.D., Rivera M.M., Prell R., et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. Journal of Immunology 2000, 164(4):2160-2169.
164. Wilcox R.A., Chapoval A.I., Gorski K.S., et al. Cutting edge: Expression of functional CD137 receptor by dendritic cells. Journal of Immunology 2002, 168(9):4262-4267.
165. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. The New England Journal of Medicine 2013, 369(2):122-133.
166. Wolchok J.D., Neyns B., Linette G., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. The Lancet Oncology 2010, 11(2):155-164.
167. Woo S.R., Turnis M.E., Goldberg M.V., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Research 2012, 72(4):917-927.
168. Workman C.J., Vignali D.A. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. European Journal of Immunology 2003, 33(4):970-979.
169. Zamarin D., Holmgaard R.B., Subudhi S.K., et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Medicine 2014, 6(226):226ra232.
170. Zeng J., Harris T.J., Lim M., Drake C.G., Tran P.T. Immune modulation and stereotactic radiation: Improving local and abscopal responses. BioMed Research International 2013, 2013:658126.